Xia S - Search Results

1

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.

Miner PB Jr, Wedel MK, Xia S, Baker BF. Miner PB Jr, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13. doi: 10.1111/j.1365-2036.2006.02837.x. Aliment Pharmacol Ther. 2006. PMID: 16669955 Clinical Trial.

2

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. van Deventer SJ, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25. doi: 10.1111/j.1365-2036.2006.02910.x. Aliment Pharmacol Ther. 2006. PMID: 16669956 Clinical Trial.

3

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.

Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK. Miner PB Jr, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34. doi: 10.1111/j.1365-2036.2006.02909.x. Aliment Pharmacol Ther. 2006. PMID: 16669957 Clinical Trial.

4

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.

Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, Salgado N, Bui HH, Hart CE, Burel SA, Younis HS, Geary RS, Henry SP, Bhanot S. Crooke ST, et al. Among authors: xia s. Mol Ther. 2016 Oct;24(10):1771-1782. doi: 10.1038/mt.2016.136. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357629 Free PMC article.

5

Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience.

Crooke ST, Baker BF, Xia S, Yu RZ, Viney NJ, Wang Y, Tsimikas S, Geary RS. Crooke ST, et al. Among authors: xia s. Nucleic Acid Ther. 2019 Feb;29(1):16-32. doi: 10.1089/nat.2018.0753. Epub 2018 Dec 20. Nucleic Acid Ther. 2019. PMID: 30570431 Free PMC article. Clinical Trial.

6

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Loomba R, et al. Among authors: xia s. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):829-838. doi: 10.1016/S2468-1253(20)30186-2. Epub 2020 Jun 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32553151 Clinical Trial.

7

Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.

Cohn DM, Viney NJ, Fijen LM, Schneider E, Alexander VJ, Xia S, Kaeser GE, Nanavati C, Baker BF, Geary RS, Levi M, Meijers JCM, Stroes ESG. Cohn DM, et al. Among authors: xia s. N Engl J Med. 2020 Sep 24;383(13):1242-1247. doi: 10.1056/NEJMoa1915035. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877578 Clinical Trial.

8

Improvements in the Tolerability Profile of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods.

Partridge W, Xia S, Kwoh TJ, Bhanot S, Geary RS, Baker BF. Partridge W, et al. Among authors: xia s. Nucleic Acid Ther. 2021 Dec;31(6):417-426. doi: 10.1089/nat.2020.0917. Epub 2021 Jul 8. Nucleic Acid Ther. 2021. PMID: 34242101 Free PMC article.

9

Integrated Assessment of Phase 2 Data on GalNAc₃-Conjugated 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides.

Baker BF, Xia S, Partridge W, Kwoh TJ, Tsimikas S, Bhanot S, Geary RS. Baker BF, et al. Among authors: xia s. Nucleic Acid Ther. 2023 Jan;33(1):72-80. doi: 10.1089/nat.2022.0044. Epub 2022 Nov 29. Nucleic Acid Ther. 2023. PMID: 36454263 Free PMC article. Clinical Trial.

10

Safety and Tolerability of GalNAc₃-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data.

Baker BF, Xia S, Partridge W, Engelhardt JA, Tsimikas S, Crooke ST, Bhanot S, Geary RS. Baker BF, et al. Among authors: xia s. Nucleic Acid Ther. 2024 Feb;34(1):18-25. doi: 10.1089/nat.2023.0026. Epub 2024 Jan 16. Nucleic Acid Ther. 2024. PMID: 38227794 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,440 results

Search Page

Filters